Impacting inflammation through mechanistic target of rapamycin (IMTOR) - inflammatory diseases limit healthspan, defined as the length of one's life spent in good health

Active Project Grant Awarded Last action

Award ID
R01AG084180
Recipient
Awarding agency
Obligated
$1,855,634

Award facts

Assistance listing
93.866 Aging Research
Completion date 59% complete
Place of performance
Lexington, KY 40536, USA

Award details come from USAspending.gov.

Description

We propose an ancillary study to an NIA-funded trial U01AG076941 (EVERLAST) that we call impacting inflammation through mechanistic target of rapamycin (IMTOR). The EVERLAST parent trial will test the ability of low/intermittent doses of the rapamycin analogue everolimus to selectively inhibit MTORC1 but not MTORC2, and thus improve multiple indicators of healthspan, while avoiding the undesirable side-effects of rapamycin. Analysis of immune cells as major sources of mtor-regulated inflammation, coupled with analysis in the context of parent trial outcomes, would significantly enhance the value of EVERLAST without changing subject burden. IMTOR thus responds to not-AG-23-020 "maximizing the scientific value of secondary analysis of existing cohorts and datasets in order to address research gaps and foster additional opportunities in aging research". EVERLAST is enrolling middle-aged to older adults who are generally healthy but are overweight/obese and insulin resistant to take placebo or everolimus daily (0.5MG), or everolimus once weekly (5MG) for 24 WKS. EVERLAST will determine the impact of this intervention on fundamental hallmarks of aging including changes in metabolism, muscle function, brain health, senescence, and frailty. IMTOR will expand the scope of EVERLAST beyond flu vaccine-generated immune responses by quantitating the impact of everolimus on chronic inflammation, a key cause of age-related health declines generated mainly by immune cells. IMTOR will focus mainly on CD4+ T cells based on our data showing these cells are dominant sources of inflammation in healthy and obesity-associated aging. IMTOR is designed to test the overall hypothesis that everolimus lowers the risk of age-related health problems by reducing chronic inflammation through mechanisms that include improved bioenergetics and redox balance in immune cells. We will complement primary focus on T cells with analyses of myeloid cells, the latter a secondary source of systemic inflammation. Mechanistic insights into everolimus action on immune cells will be analyzed relative to changes in hallmarks of aging collected for EVERLAST. We will compare mitochondrial outcomes between immune cells and skeletal muscle to challenge the assumption of similar everolimus impacts on distinct tissue types. Parallel EX vivo manipulations will establish cause/effect relationships amongst everolimus, MTORC1/2 function, cell physiology, cytokine profiles, and the frequency of polyfunctional T cells, a newly appreciated modulator of inflammatory disease. Success with the proposed project coupled with EVERLAST outcomes will determine safety and efficacy of everolimus for promoting healthspan in our ever-aging population.

Transactions

Action Obligated Date
Amendment $611,775
Amendment $603,791
Original award $640,068

Subawards

Subrecipient Amount Awarded
University Of Wisconsin System Dr. Konopka coordinates the research team at University of Wisconsin-Madison. Dr. Konopka has designed the ongoing clinical trial and his lab is performing… $100,675
University Of Wisconsin System $99,915
University Of Wisconsin System $100,675
Merrimack College Dr. Bharath will perform confocal microscopy on samples that have very few cells to capture information on lysosomal, mitochondrial biology and function and… $37,839

Quick answers

Who received award R01AG084180?

R01AG084180 was awarded to The University Of Kentucky Research Foundation by National Institute on Aging (National Institutes of Health) on August 30, 2024.

How much is award R01AG084180 worth?

$1,855,634 has been obligated on R01AG084180.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award